Rising Preference for Generic Drug Variants to Negatively Impact Global Kidney Cancer Drugs Market
Kidney Cancer Drugs Market (Major Drugs: Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), Votrient (Pazopanib)) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
According to the latest research report released by Transparency Market Research, the global kidney cancer drugs market is expected to grow consistently at a CAGR of 6.6% during the period between 2014 and 2020. The report titled “Kidney Cancer Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” forecasts that in 2013, the global kidney cancer drugs market was worth US$2.6 billion and with consistent growth, the market will be valued at US$4.5 billion by 2020.
Browse the full Kidney Cancer Drugs Market report at
According to the World Cancer Research Fund International, kidney cancer is the twelfth most common cancer in the world. Also known as Renal Cell Carcinoma (RCC), it is associated with smoking, obesity, and reduced physical activity. The report mentions that the rise in the reported cases of kidney cancer worldwide along with rising geriatric population will fuel the growth of the global kidney cancer drugs market. The report cites that the growth of the global kidney cancer drugs market will get fuelled by the approval and commercialization of novel molecules in treating kidney cancer. However, the high cost of the drugs will deter the growth of the global kidney cancer drugs market. The report predicts that the increasing preference of generic drug variants will negatively impact the global kidney cancer drugs market.
The report studies the global kidney...